MedTrace Logo

Determination In-vivo KUF for Diacap Pro Hemodialyser

NCT02964429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-02-07

No results posted yet for this study

Summary

The main purpose of this study is the determination of the in-vivo ultrafiltration coefficient (in-vivo KUF) for Diacap Pro dialyzers following routine dialysis prescription in the United States.

Conditions

  • Kidney Failure,Chronic
  • Renal Insufficiency,Chronic
  • Kidney Disease, End-Stage
  • Kidney Insufficiency

Interventions

DEVICE

Diacap Pro High-Flux

During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.

Sponsors & Collaborators

  • Winicker Norimed GmbH

    collaborator INDUSTRY

  • B.Braun Avitum AG

    lead INDUSTRY

Principal Investigators

  • Vladimir Polakovic, Prim. MUDr. · Interni oddeleni Strahov VFN

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-14
Primary Completion
2016-12-23
Completion
2016-12-23

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02964429 on ClinicalTrials.gov